PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biotechnology company developing cell-based therapies for chronic kidney disease, operating in the regenerative medicine sector. The company went public in January 2023 through a business combination with Social Capital Suvretta Holdings Corp. IV, a blank-check vehicle sponsored by a partnership between Social Capital and Suvretta Capital Management that completed its IPO in 2021. ProKidney is advancing its lead candidate, REACT, through clinical development and filed its most recent quarterly report on Form 10-Q with the SEC on May 15, 2026. For in-depth data, filings, and analytics on PROK and the full SPAC universe, sign up for complete access at SpacDesk.